Slovenia has temporarily suspended the use of Johnson & Johnson's (NYSE:JNJ) COVID-19 vaccines after the death of a young woman, Reuters news agency reported on Wednesday, citing the STA national news agency.
STA reported that the patient had blood clots and bleeding in the brain at the same time and intensive care was not successful.
Health minister Janez Poklukar said he was not familiar with the details of the case.
"I can't make comments, but the conditions have been met for clarifying all the circumstances of what happened," he said.
The J&J Janssen COVID-19 vaccine is one of the several vaccines Slovenia is using in its vaccination programme.
Allergy Therapeutics reports positive interim results for G306 Phase III trial
Valneva Austria GmbH receives USFDA approval for Ixchiq
Actinium Pharmaceuticals names chief business officer
YS Biopharma completes enrolment for PIKA Rabies Vaccine phase three clinical trial
Rational Vaccines signs contract with Shenzhen Mellow Hope Pharm Industrial
Moderna and CEPI partner to accelerate mRNA vaccine development
Orexo names new board director
GSK's Arexvy shows promise in RSV vaccine trial for adults 50-59
Inimmune signs research collaboration with Boston Children's Hospital